Clinical Trials Browser

Phase 1 × Withdrawn × SNX-5422 × Clear all

NCT02914327 2018-07-30

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell